PSNL Personalis, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1527753 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.9%
TTM net income YoY-61.5%
TTM EPS YoY-39.8%
Revenue 3-yr CAGR4.6%
Net income 3-yr CAGR—
Margins
Gross margin16.7%
Operating margin-156.7%
Net margin-147.7%
FCF margin-133.3%
EBITDA margin-144.6%
Returns
ROE-62.1%
ROA-44.7%
ROIC (approx.)-84.8%
Asset turnover0.30x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio4.53x
Interest coverage-683.98x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.60M | $22.36M | $15.47M | $17.34M | $14.49M | $17.20M | $20.61M | $16.80M |
| Cost of revenue | $19.03M | $17.61M | $15.19M | $15.45M | $12.58M | $12.45M | $13.40M | $12.25M |
| Gross profit | $6.57M | $4.74M | $281,000 | $1.90M | $1.91M | $4.76M | $7.21M | $4.55M |
| R&D expense | $16.07M | $16.34M | $14.54M | $13.07M | $12.17M | $12.38M | $12.64M | $11.49M |
| SG&A expense | $26.01M | $22.00M | $17.90M | $14.09M | $13.03M | $14.18M | $12.26M | $11.17M |
| Operating income | -$35.52M | -$33.59M | -$32.16M | -$25.27M | -$23.29M | -$21.80M | -$17.70M | -$18.11M |
| Interest expense | $36,000 | $37,000 | $47,000 | $65,000 | $64,000 | $48,000 | $28,000 | -$1,000 |
| Pretax income | -$33.80M | -$31.68M | -$30.02M | -$23.80M | -$21.65M | -$20.05M | -$15.74M | -$16.42M |
| Income tax | $3,000 | $5,000 | $16,000 | $9,000 | $3,000 | $2,000 | $7,000 | $4,000 |
| Net income | -$33.80M | -$31.68M | -$30.03M | -$23.81M | -$21.65M | -$20.06M | -$15.75M | -$16.43M |
| EBITDA | -$33.04M | -$31.18M | -$29.79M | -$22.80M | -$20.89M | -$19.27M | -$15.11M | -$15.57M |
| EPS (basic) | -0.32 | -0.30 | -0.29 | — | -0.24 | -0.23 | -0.18 | — |
| EPS (diluted) | -0.32 | -0.30 | -0.29 | — | -0.24 | -0.23 | -0.18 | — |
| Weighted avg. shares (diluted) | 107.21M | 105.42M | 104.19M | — | 88.70M | 88.52M | 87.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $98.27M | $93.97M | $73.59M | $124.25M | $49.97M | $53.37M | $71.00M | $91.42M |
| Short-term investments | $92.33M | $118.69M | $159.62M | $115.71M | $100.54M | $119.86M | $114.69M | $93.59M |
| Receivables | $18.04M | $15.10M | $13.02M | $16.20M | $14.38M | $9.95M | $10.97M | $8.14M |
| Current assets | $223.05M | $245.05M | $258.20M | $267.95M | $174.40M | $193.34M | $206.42M | $203.01M |
| PP&E, net | $50.32M | $48.57M | $48.44M | $44.81M | $47.00M | $45.81M | $47.99M | $48.27M |
| Total assets | $291.60M | $312.13M | $325.39M | $334.16M | $242.84M | $258.68M | $273.31M | $270.27M |
| Current liabilities | $49.27M | $46.38M | $39.05M | $39.63M | $36.16M | $31.72M | $29.89M | $31.13M |
| Total liabilities | $78.93M | $76.97M | $70.63M | $72.98M | $71.42M | $67.85M | $65.96M | $67.31M |
| Shareholders' equity | $212.67M | $235.16M | $254.76M | $261.19M | $171.41M | $190.83M | $207.34M | $202.96M |
| Shares outstanding | 108.38M | 106.37M | 104.69M | 102.48M | 88.75M | 88.65M | 88.32M | 85.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.07M | -$25.77M | -$22.48M | -$22.25M | -$21.80M | -$12.94M | -$17.96M | -$7.80M |
| Capital expenditure | $3.07M | $3.78M | $3.19M | $77,000 | $1.63M | $290,000 | $2.51M | $1.25M |
| Free cash flow | -$30.14M | -$29.55M | -$25.67M | -$22.32M | -$23.43M | -$13.22M | -$20.47M | -$9.04M |
| Investing cash flow | $24.01M | $38.16M | -$46.01M | -$14.38M | $18.72M | -$4.37M | -$22.54M | -$26.18M |
| Financing cash flow | $7.37M | $7.99M | $17.83M | $110.89M | -$317,000 | -$327,000 | $20.09M | $49.60M |
| Depreciation & amortization | $2.48M | $2.41M | $2.37M | $2.46M | $2.40M | $2.53M | $2.59M | $2.54M |
| Stock-based compensation | $3.91M | $3.98M | $2.55M | $2.30M | $2.08M | $2.83M | $2.22M | $2.67M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.